The UK and US have secured a significant trade agreement that will preserve no tariffs on UK medicine products entering the American market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to increase funding on medicines through the National Health Service (NHS). This commitment guarantees that duties on these key products will be held at zero for a timeframe of three years.
This deal is in response to previous warnings to significantly raise import taxes on branded drug imports, with figures floated reaching 100%.
"This arrangement with the UK strengthens the international landscape for innovative medicines and introduces much-needed equity to transatlantic medicine commerce," a statement noted.
Commercial Impact
Pharmaceuticals represent one of the UK's largest exports to the America, which is by far the largest market for leading British pharmaceutical firms.
Statistics reveal that in the year to the end of last September, the UK exported medicines totaling £11.1bn to the US. This value made up a significant portion of total UK exports in that timeframe.
"This guarantee secures jobs, stimulates investment and paves the way for the UK to emerge as a worldwide center for biotech and pharma," a minister stated.
Detailed NHS Changes
The deal includes several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to raise total NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The amount manufacturers must return to the NHS to prevent overspending will be limited at 15%. In the past, refunds topped twenty percent.
Recent Tensions
This agreement takes place against a long-running dispute between the pharmaceutical industry and the UK government over spending levels and approval rates.
These tensions were heightened by assertions that American patients were charged several times more for the same drugs than consumers in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been paused or abandoned, while multi-billion-dollar investments have been pledged toward US facilities.
One official acknowledged that the NHS must increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a share of its total funding over the last ten years.
